SCHEMBL64509

SCHEMBL64509

O=C(NC12CCC(CC1)Cn1c2nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)c1ccnc(OCC(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.43
KCNH2 Q12809 2/20 0.40
CYP2C9 P11712 2/20 0.39
CALCA P06881 1/20 0.35
MMP13 P45452 1/20 0.35
KCNE1 P15382 1/20 0.35
CCR1 P32246 1/20 0.35
KCNQ1 P51787 1/20 0.35
TTK P33981 2/20 0.34
ERCC1 P07992 1/20 0.33
FEN1 P39748 1/20 0.33
ERCC4 Q92889 1/20 0.33
KLKB1 P03952 1/20 0.33
CYP2C19 P33261 2/20 0.32
CYP1A2 P05177 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
HTR2B P41595 1/20 0.32
CYP2J2 P51589 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL52520 0.85 L3MBTL1 (0.47) KCNH2CYP2C9CALCAKCNE1CCR1
SCHEMBL64512 0.85 KCNH2 (0.44) KCNH2CYP2C9CALCAKCNE1CCR1
SCHEMBL64514 0.84 KCNH2 (0.42) KCNH2CYP2C9CALCAKCNE1CCR1
SCHEMBL52562 0.83 KCNH2 (0.45) KCNH2CYP2C9CALCAKCNE1CCR1
SCHEMBL63488 0.83 KCNH2 (0.41) KCNH2CYP2C9CALCAKLKB1HTR2A
SCHEMBL64481 0.82 KCNH2 (0.45) KCNH2CYP2C9CALCAKCNE1CCR1
SCHEMBL52473 0.82 KCNH2 (0.43) EPHX2KCNH2CYP2C9CALCAERCC1
SCHEMBL418372 0.81 KCNH2 (0.47) KCNH2CYP2C9CALCAKCNE1CCR1
SCHEMBL63481 0.81 PLD1 (0.41) KCNH2CYP2C9CALCAERCC1FEN1
SCHEMBL62574 0.81 NAMPT (0.46) CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG EPHX2 4099/4885KCNH2 3969/4885CYP2C9 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.